Cyprotex PLC New DDI-Fusion
06 Outubro 2016 - 3:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
06 October 2016
Cyprotex PLC
("Cyprotex" or "the Company")
New DDI-Fusion Combines Chemical Structure with In Vitro
Data
to Predict Human Drug-Drug Interactions.
Cyprotex PLC (AIM:CRX), a specialist Contract Research
Organisation (CRO), announced today the launch of DDI-Fusion, which
predicts human drug-drug interactions (DDI) from chemical structure
combined with in vitro data.
Drug-drug interactions occur when multiple drugs are
administered to a patient and one or more of these drugs have the
ability to interact with the metabolism or transport of the
co-administered drug(s), leading to changes in plasma
concentrations and potentially reduced efficacy (therapeutic
effect) or enhanced toxicity. The importance of DDI is growing due
to our aging population and the increasing use of polypharmacy with
this population and in other conditions such as cancer or HIV.
DDI-Fusion utilises Cyprotex's chemPK(TM) tool to predict key
pharmacokinetic parameters as inputs to the model. It combines
these inputs with in vitro data related to DDI mediated via CYP3A4,
one of the main drug metabolising enzymes in the body, in order to
predict the potential effects on drugs metabolised by this enzyme.
The software can also be used to predict interactions with other
metabolising enzymes within the body. DDI-Fusion has several
advantages over existing techniques in that it uses robust
physiologically-based pharmacokinetic (PBPK) modelling techniques
and does not require any clinical data as inputs to the model.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments:
"DDI-Fusion is the latest addition to a suite of powerful,
interconnected in silico tools to assist scientists in
decision-making early in the drug discovery process. Prediction of
pharmacokinetics by chemPK(TM) drives the prediction of DDI by
DDI-Fusion using a unique algorithm developed here at Cyprotex. The
approach is logical, adaptable and robust, and performs favourably
compared to the mechanistic static approach currently promoted by
the regulatory authorities."
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1500 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemPK(TM),
chemTarget, chemTox and DDI-Fusion, and a range of skin, ocular and
endocrine disruption services. For more information, please visit
www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABSBDGDXGBGLU
(END) Dow Jones Newswires
October 06, 2016 02:00 ET (06:00 GMT)
Cyprotex (LSE:CRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cyprotex (LSE:CRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024